HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO New Ruipeng Pet Group (RPET.US)- The Industry, the Business and the Concerns

I-Mab (IMAB.US) - An "Entertaining Bet": To Be a Dark Horse or to Fail Completely

Pre-IPO Changchun BCHT Biotechnology - The Risk of Single-Product Dependence and Uncertain Outlook

Angelalign Technology (6699.HK) - About the Share Price Rebound, the Outlook and the Challenges

Presentation for Webinar: China Healthcare - Outlook and Opportunities in 2023

CanSino Biologics (6185.HK/688185.CH) - Time to Offload; the Rally May Not Last Long

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

CanSino Biologics  / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/cansino-biologics-inc" target="_blank" data-smartkarma-citation="entities:27739:1" rel="noopener">CanSino Biologics Inc (6185 HK)</a> disclosed plans to publicly list in Switzerland, but the story of the fourth dose of COVID-19 vaccine is difficult to boost its stock price/valuation. </li>
<li>According to CanSino’s management,MCV4’s commercialization faced some challenges, which means 2022 annual performance may not be good. 2021 would probably be a high point of CanSino’s performance in recent years.</li>
<li>Share price could pullback when 2022 annual report is released, which offers a better opportunity if investors want to go long, considering CanSino's long-term investment value analyzed in prior insights. </li>
</ul>



CanSino Biologics Inc (6185 HK) disclosed plans to publicly list in Switzerland, but the story of the fourth dose of COVID-19 vaccine is difficult to boost its stock price/valuation. 
According to CanSino’s management,MCV4’s commercialization faced some challenges, which means 2022 annual performance may not be good. 2021 would probably be a high point of CanSino’s performance in recent years.
Share price could pullback when 2022 annual report is released, which offers a better opportunity if investors want to go long, considering CanSino's long-term investment value analyzed in prior insights. 


Chongqing Zhifei Biological Products (300122 CH)

Pre-IPO CanSino Biologics - 2022 Annual Results May Be Ugly as MCV4 Commercialization Hit a Snag